European Companies Search Engine
EU funding (€187,624): SMART-AML: Shaping Marrow Adiposity to Redefine Treatment in Acute Myeloid Leukemia Hor6 May 2024 EU Research and Innovation programme "Horizon"
Overview
Text
SMART-AML: Shaping Marrow Adiposity to Redefine Treatment in Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy characterized by the uncontrolled proliferation of myeloid cells, which hijack the bone marrow (BM) and compromise its physiological functions. AML prognosis remains poor, with <10% of patients above 60 years old surviving after 5-years. Recent discoveries have revealed the key role of BM microenvironment in harboring and protecting leukemic stem cells from chemotherapy, contributing to AML relapse. Therefore, targeting the hijacked BM niche and transforming it into a “tumor-inhospitable” microenvironment represents a promising therapeutic strategy. In adults, bone marrow adipose tissue (BMAT) is the predominant component of the BM microenvironment, making it an appealing target. However, the role of BMAT in AML development, drug resistance and survival is still controversial. With SMART-AML, I aim at identifying AML cells-related changes within the BMAT/BM microenvironment, to introduce BMAT manipulation as therapeutic strategy to sensitize leukemic cells to chemotherapy. To achieve this goal, I will exploit state-of-the-art bioprinting technologies to engineer a perfusable, humanized bone/BMAT 3D biomimetic microenvironment. Patient-derived AML cells will be cultured within the engineered platform to characterize the AML-induced BMAT changes in a controlled environment, with limited variables. Finally, BMAT will be manipulated (i.e. expanded or reduced), to determine the potential of this therapeutic approach on enhancing the efficacy of chemotherapy on leukemic stem cells and reducing the chance of relapse. This project will prepare me to become a tenured scholar, strengthening my academic profile and enabling me to establish myself as an independent principal investigator with a research line on advanced bone disease modeling. It will also create opportunities to perform cutting-edge research at the intersection between tissue engineering and cancer research.
Funded Companies:
| Company name | Funding amount |
| UNIVERSITAIR MEDISCH CENTRUM UTRECHT | €187,624 |
Source: https://cordis.europa.eu/project/id/101153517
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Universitair Medisch Centrum Utrecht, Utrecht, Netherlands.
The visualizations for "UNIVERSITAIR MEDISCH CENTRUM UTRECHT - EU funding (€187,624): SMART-AML: Shaping Marrow Adiposity to Redefine Treatment in Acute Myeloid Leukemia"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
